drugset / Trial / NCT00715442

Pre-Surgical Sutent in Renal Cell Carcinoma (RCC)

NCT00715442 ↗

Phase 2 Active not recruiting 50 enrolled M.D. Anderson Cancer Center Pfizer · collab
NaSingle-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to learn if Sutent® (sunitinib malate), given before surgery, can help control renal cell carcinoma. The safety of sunitinib malate will also be studied.

Timeline

Start
2008-06-24
Primary completion
2026-12-04
Completion
2026-12-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Sunitinib Small molecule 50 mg Oral

Indications